NSE filing, NSE: STAR. Summary written from the filing by ALFA Finder's alert engine.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,100.90
- Market cap
- ₹10,147 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.5×Sector 46.1×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026
Strides Pharma Science Investor Presentation: Key Takeaways
Q2FY27 revenue ₹14,297m (+17.1% YoY), EBITDA ₹2,509m (17.6% margin), reported PAT ₹1,341m (+2.0%). Ex-US revenue surpassed US for the first time; US ~$375m FY28 aspiration pushed beyond FY28.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Strides Pharma Science Q2 FY27 Results: Net Profit ₹134.1 Cr, Up 2.0% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,430 Cr (+17.1% YoY) and net profit of ₹134.1 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹134.1 Cr · +2.0% YoY
Strides Pharma Science Board Meeting Date
Strides Pharma will hold a board meeting on 29 October 2026 to consider unaudited quarterly and half-year results. Trading window stays closed from 1 October until 48 hours after results.
Strides Pharma Science Other Announcement
Strides Pharma Science Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Other employee stock options announcements
All →Archean Chemical Industries Employee Stock Options
Archean Chemical allotted 6,143 equity shares to one grantee under its ESOP 2022 on 29-Oct-2026. Paid-up capital rose to 12,34,64,537 shares.
Intellect Design Arena Employee Stock Options
Intellect Design Arena granted 1,83,500 RSUs to 19 associates under its ISOP/RSU 2016 scheme. This ESOP grant carries no transaction value for the event.
- Execution
- Vesting over 1st to 5th year from grant
Edelweiss Financial Services Employee Stock Options
Edelweiss Financial Services allotted 4,42,792 equity shares under its employee stock incentive and appreciation rights plans. No consideration amount is stated, so no event value applies.
Raymond Realty Employee Stock Options
Raymond Realty allotted 1,04,211 equity shares to its ESOP Trust under the RRL ESOP Scheme 2025 following option exercises. Paid-up capital rose to Rs 66.68 Crore.
Shaily Engineering Plastics Employee Stock Options
Shaily Engineering Plastics allotted 1,300 equity shares to employees on exercise of ESOPs at Rs. 732 per share under its 2019 plan. Issued paid-up capital rises to 4,59,96,548 shares of Rs. 2 each.
Info Edge (India) Employee Stock Options
Info Edge's employee stock option trust sold 1,439 shares on 26 October 2026 under the ESOP scheme. The disposal reduces the trust's holding to 410,707 shares.